share_log

EF Hutton Initiates Coverage On TCR2 Therapeutics With Hold Rating, Announces Price Target of $2

Benzinga Real-time News ·  Jan 5, 2023 04:33

EF Hutton analyst Tony Butler initiates coverage on TCR2 Therapeutics (NASDAQ:TCRR) with a Hold rating and announces Price Target of $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment